Oppenheimer Maintains Outperform on Medicenna Therapeutics, Lowers Price Target to $3
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Matthew Biegler has maintained an Outperform rating on Medicenna Therapeutics (NASDAQ:MDNA), but lowered the price target from $8 to $3.
August 14, 2023 | 4:12 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Medicenna Therapeutics' price target has been lowered from $8 to $3 by Oppenheimer, though the Outperform rating is maintained.
The lowering of the price target by Oppenheimer indicates a potential decrease in the stock's value. However, the maintained Outperform rating suggests that the stock is still expected to outperform others in the market. This mixed signal could lead to short-term uncertainty and potential downward pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100